ClinicalTrials.gg
TerminatedNCT05328102Updated Apr 30, 2024Results posted

Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)

A Phase 2 interventional study of Plamotamab and Tafasitamab in Diffuse Large-cell B-cell Lymphoma, sponsored by Xencor, Inc.. Terminated at 3 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-30.

Sponsored by Xencor, Inc. · Phase 2, Interventional, and Treatment

Why this study was terminated
The study has been terminated early by the sponsor due to business decision.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
3
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,131 studies in Lymphoma, Large B-Cell, Diffuse with a site in United States — 126 open to participants now, 217 under way, 18 of them phase 3. Lymphoma, Large B-Cell, Diffuse · United States.

Enrollment
894th of 963
3 · median 37
Started
2022
with 36 others
Phase 2
380 of 1,131
47 open now
Registered
979th of 1,131
by date

Among the 1,131 studies in Lymphoma, Large B-Cell, Diffuse with a site in United States, this one is the 894th largest by enrollment of the 963 interventional ones that give a count, is one of 37 that started in 2022, is one of 380 in phase 2, and was the 979th registered.

Lymphoma, Large B-Cell, Diffuse

1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

126 of the 1,131 studies in Lymphoma, Large B-Cell, Diffuse with a site in United States are open now. Recruiting first, the newest first:

121 more — sign in →

All 126 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,131 studies in Lymphoma, Large B-Cell, Diffuse with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the safety and effectiveness of plamotamab when it is given with tafasitamab and lenalidomide in participants with relapsed or refractory DLBCL.

Read the detailed description

This is a randomized, multicenter, open-label, Phase 2 study of plamotamab combined with tafasitamab plus lenalidomide versus tafasitamab plus lenalidomide in adult participants with DLBCL who have relapsed after or are refractory to at least 1 prior line of therapy, which must have included multi-agent chemoimmunotherapy inclusive of an anti-cluster of differentiation (CD) 20 monoclonal antibody, and who are not candidates for autologous stem-cell transplantation (ASCT), refuse ASCT, or relapse after ASCT.

The study was planned to be performed sequentially, with Part 1A (Safety run-in, with a lower plamotamab dose), Part 1B (Safety run-in, with the target plamotamab dose) and Part 2 (Open-Label, randomized). The study was terminated by the Sponsor during Part 1A of the study. No participants were enrolled in Part 1B or Part 2.

03

Conditions studied

  • Diffuse Large-cell B-cell Lymphoma

Keywords

  • DLBCL, NOS
  • Diffuse Large B-cell Lymphoma
  • Transformed indolent Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • confirmed diagnosis of DLBCL, not otherwise specified, including DLBCL arising from low grade lymphoma
  • CD20+ and CD19+ lymphoma
  • Archival paraffin embedded tumor tissue or unstained slides must be available for retrospective cell of origin determination
  • At least 1 prior systemic line(s) of therapy, one of which must have included multi-agent chemoimmunotherapy that includes an anti-CD20 monoclonal antibody.
  • At least 1 bidimensionally site. The lesion must have a greatest transverse diameter of ≥ 1.5 centimeter (cm) and greatest perpendicular diameter of ≥ 1.0 cm at baseline. The lesion must have a positive finding on positron emission tomography (PET) scan
  • Ineligible for or refuse hematopoietic stem cell transplantation ().
  • (ECOG) performance status of 0 to 2
  • Completed vaccination for the SARS-CoV-2 virus prior to study entry
  • Fertile participants must agree to use 2 highly effective methods of during for at least 6 months (male participants) and 8 months (female participants) after the last dose of study treatment

Exclusion Criteria:

  • Any other histological type of lymphoma, including high-grade B-cell lymphoma, including those with myelocytomatosis oncogene (MYC) and B-cell lymphoma 2 (BCL2) and/or B-cell lymphoma 6 (BCL6) rearrangements primary mediastinal (thymic) large B cell (PMBL) or Burkitt lymphoma
  • A prior diagnosis of chronic lymphocytic leukemia (CLL) (Richter's Transformation)
  • Primary central nervous system lymphoma

Exclusionary Previous and Current Treatment:

  • Previously received treatment with an anti-CD20 × anti-CD3 bispecific antibody (bsAb)
  • Anti-CD20 therapy (for example, rituximab) within 21 days prior to study entry
  • Participants who have, within 14 days prior study entry:

    • Chemotherapy, radiotherapy, or other lymphoma-specific therapy not including anti CD20 therapy
    • Small molecule or anticancer agents within 6 elimination half-lives
    • Received within 30 days
    • Required systemic anti-infective therapy for active, intercurrent infections
  • Participants who have had the following prior therapies or treatments:

    • Were previously treated with CD19-targeted therapy, including chimeric antigen receptor-T cell (CAR-T), unless current is CD19+
    • Have a history of to compounds of similar biological or chemical composition to tafasitamab, immunomodulatory imide drugs (IMiDs)
    • Previous allogenic stem cell transplantation
    • Have a history of deep venous thrombosis/embolism, threatening thromboembolism
    • Concurrently use other anticancer or experimental treatments
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    Part 1A: Plamotamab (lower dose), Tafasitamab, and Lenalidomide

    Drug: Plamotamab will be administered at a lower dose in addition to tafasitamab (12 milligrams \[mg\]/kilograms \[kg\] intravenously) plus lenalidomide (25 mg orally). This cohort was planned to enroll sequentially prior to Part 1B.

    Biological: Plamotamab · Biological: Tafasitamab · Drug: Lenalidomide

  • Experimental
    Part 1B: Plamotamab (target dose), Tafasitamab, and Lenalidomide

    Drug: Plamotamab will be administered at the target dose in addition to tafasitamab (12 mg/kg intravenously) plus lenalidomide (25 mg orally). This cohort was planned to enroll sequentially after Part 1A.

    Biological: Plamotamab · Biological: Tafasitamab · Drug: Lenalidomide

  • Experimental
    Part 2A :Plamotamab, Tafasitamab, and Lenalidomide

    Drug: Plamotamab will be administered at protocol defined dose in addition to tafasitamab (12 mg/kg intravenously) plus lenalidomide 25 mg (orally).

    Biological: Plamotamab · Biological: Tafasitamab · Drug: Lenalidomide

  • Active comparator
    Part 2B: Tafasitamab and Lenalidomide

    Drug: Tafasitamab (12 mg/kg intravenously) plus lenalidomide 25 mg (orally).

    Biological: Tafasitamab · Drug: Lenalidomide

Interventions

06

What researchers measure

Primary outcomes

  1. Part 1 A: Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    An adverse event (AE) was any untoward medical occurrence in a study participant. The AE did not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign (including a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a study drug. AEs may have included the onset of new illness and the exacerbation of preexisting conditions. TEAEs were defined as events with onset dates on or after the start of study treatment or events that were present before the first infusion of study treatment and subsequently worsened in severity. A summary of serious and all other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

    Time frame: From first dose of study drug up to end of treatment (maximum treatment exposure: 303 days)

  2. Part 1 A: Number of Participants With Cytokine Release Syndrome

    Cytokine release syndrome was defined as "a supraphysiologic response following any immune therapy that results in the activation or engagement of endogenous or infused T cells and/or other immune effector cells". A summary of serious and all other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

    Time frame: From first dose of study drug up to end of treatment (maximum treatment exposure: 303 days)

07

Results

Posted Apr 30, 2024
Limitations and caveats
Due to the early termination of the study in Part 1A, only 3 participants enrolled. No participants were enrolled in Part 1B or Part 2. Safety data is limited due to the small sample size. No efficacy data was collected for the secondary outcome measures.

Participant flow

The study planned to enroll participants at 11 sites (1 in the United States, 7 in France, 2 in Spain, and 1 in South Korea). However, due to early study termination only 3 participants were enrolled and dosed at a single site in the United States.

Participant flow — Overall Study
MilestonePart 1A: Plamotamab (Lower Dose), Tafasitamab, and Lenalidomide
Started3
Received at least 1 dose of study drug3
Completed0
Not completed3

Outcome measures

PrimaryPart 1 A: Number of Participants With Treatment Emergent Adverse Events (TEAEs)

An adverse event (AE) was any untoward medical occurrence in a study participant. The AE did not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign (including a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a study drug. AEs may have included the onset of new illness and the exacerbation of preexisting conditions. TEAEs were defined as events with onset dates on or after the start of study treatment or events that were present before the first infusion of study treatment and subsequently worsened in severity. A summary of serious and all other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

Time frame:
From first dose of study drug up to end of treatment (maximum treatment exposure: 303 days)
Reported as:
Count of participants · Participants
Part 1 A: Number of Participants With Treatment Emergent Adverse Events (TEAEs)
ParticipantsPart 1A: Plamotamab (Lower Dose), Tafasitamab, and Lenalidomide
Part 1 A: Number of Participants With Treatment Emergent Adverse Events (TEAEs)3
PrimaryPart 1 A: Number of Participants With Cytokine Release Syndrome

Cytokine release syndrome was defined as "a supraphysiologic response following any immune therapy that results in the activation or engagement of endogenous or infused T cells and/or other immune effector cells". A summary of serious and all other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

Time frame:
From first dose of study drug up to end of treatment (maximum treatment exposure: 303 days)
Reported as:
Count of participants · Participants
Part 1 A: Number of Participants With Cytokine Release Syndrome
ParticipantsPart 1A: Plamotamab (Lower Dose), Tafasitamab, and Lenalidomide
Part 1 A: Number of Participants With Cytokine Release Syndrome2

Adverse events

Collected over From first dose of study drug up to end of treatment (maximum treatment exposure: 303 days). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1A: Plamotamab (Lower Dose), Tafasitamab, and Lenalidomide1/3 (33.3%)3/3 (100%)3/3 (100%)
Most frequent serious events
Most frequent serious events
EventPart 1A: Plamotamab (Lower Dose), Tafasitamab, and Lenalidomide
Cytokine release syndromeImmune system disorders1/3
PneumoniaInfections and infestations1/3
Small intestinal haemorrhageGastrointestinal disorders1/3
HypertransaminasaemiaHepatobiliary disorders1/3
Pneumonia aspirationInfections and infestations1/3
ConstipationGastrointestinal disorders1/3
DysphagiaGastrointestinal disorders1/3
Volvulus of small bowelGastrointestinal disorders1/3
Most frequent other events
Showing 10 of 42
Most frequent other events
EventPart 1A: Plamotamab (Lower Dose), Tafasitamab, and Lenalidomide
Cytokine release syndromeImmune system disorders2/3
FatigueGeneral disorders2/3
RashSkin and subcutaneous tissue disorders2/3
PyrexiaGeneral disorders2/3
HypokalaemiaMetabolism and nutrition disorders2/3
HypomagnesaemiaMetabolism and nutrition disorders2/3
HypophosphatemiaMetabolism and nutrition disorders2/3
Urinary tract infectionInfections and infestations2/3
Immune effector cell-associated neurotoxicity syndromeNervous system disorders1/3
MyalgiaMusculoskeletal and connective tissue disorders1/3

Baseline characteristics

Enrolled Analysis Set: All participants who signed the informed consent form, were determined to be eligible, and received Day -8 tafasitamab dose (Study Day 1). The study was terminated by the Sponsor during Part 1A of the study. No participants were enrolled in Part 1B or Part 2.

Age, Customized
Age, Customized(Participants)Part 1A: Plamotamab (Lower Dose), Tafasitamab, and Lenalidomide
>=18 years3
Sex: Female, Male
Sex: Female, Male(Participants)Part 1A: Plamotamab (Lower Dose), Tafasitamab, and Lenalidomide
Female—
Male—
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1A: Plamotamab (Lower Dose), Tafasitamab, and Lenalidomide
Hispanic or Latino—
Not Hispanic or Latino—
Unknown or Not Reported—
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 1A: Plamotamab (Lower Dose), Tafasitamab, and Lenalidomide
American Indian or Alaska Native—
Asian—
Native Hawaiian or Other Pacific Islander—
Black or African American—
White—
More than one race—
Unknown or Not Reported—
08

Study locations

3 sites
  • Swedish Cancer Center
    Seattle, Washington 98104, United States
  • CHU de Rennes - Hopital de Pontchaillou
    Rennes Cedex, France
  • Hospital Universitario Virgen de las Nieves
    Granada, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2022 to primary completion in Feb 2023, 10 months.

Results were first posted in Apr 2024, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2022
First posted
Apr 14, 2022
StartActual
Apr 15, 2022
Primary completionActual
Feb 21, 2023
CompletionActual
Feb 21, 2023
Results first posted
Apr 30, 2024
Last update
Apr 30, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05328102
Lead sponsor
Xencor, Inc.
Responsible party
Sponsor
First posted
Apr 14, 2022
Start date
Apr 15, 2022
Primary completion
Feb 21, 2023
Completion
Feb 21, 2023
Results posted
Apr 30, 2024
Last update
Apr 30, 2024

Study contacts

Michael Chiarella
study director · Senior Director, Clinical Science, Clinical Development

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Plamotamab

Start the discussion